SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (196)6/9/2004 3:21:01 PM
From: tuck  Read Replies (1) of 255
 
It would appear that night time glucose levels, which derailed AERx, weren't measured in Exubera long term safety studies. From this year's ADA meeting:

>>Sustained Long-Term Efficacy and Safety of Inhaled Insulin during 4 Years of Continuous Therapy

Abstract Information
Abstract Number: 486-P
Authors: JAY SKYLER, FOR THE EXUBERA® PHASE II STUDY GROUP
Institution: Miami, FL
Results: Inhaled insulin has shown encouraging efficacy and safety data in short-term clinical trials. This study examined whether these favorable results are maintained in the long term. Continued open-label inhaled insulin therapy was offered to patients with diabetes who had completed any of three 3-month, randomized, controlled clinical trials (type 1, insulin-treated type 2 or type 2 diabetes uncontrolled on oral agents [OAs]). A total of 204 patients entered the extension, with 159 electing to stay on inhaled insulin (INH) or switch from comparator treatments and 89 patients having received at least 4 years of INH therapy. A small group of patients (n=23) on OAs or subcutaneous insulin was followed for up to 2 years as well. Mean (± SD) HbAì1cí was 8.23 ± 1.21% after 4 years in INH patients compared with 8.71 ± 1.49% at the start of INH treatment. Inhaled insulin dose increased slightly from 0.15 mg/kg after 3 months of treatment to 0.18 mg/kg after 4 years. The rate of overall hypoglycemia decreased from 2.58 episodes/subject month (first 4 weeks of INH treatment) to 1.50 after 4 years (final 6 months). Annualized changes in the lung function parameters FEVì1í and DLìCOí (mean ± SE) in INH patients over 4 years were -0.057 ± 0.004 L/yr and -0.376 ± 0.067 mL/min/mmHg/yr, respectively. Corresponding declines in non-INH patients (based on 2-year data only) were -0.071 ± 0.023 L/yr and -0.673 ± 0.423 mL/min/mmHg/yr, respectively. In conclusion, glycemic control and pulmonary function are well maintained during long-term continuous inhaled insulin therapy.<<

So my question is, why has ARDM/Novo made this measurement while NKTR and partners have not? Will the FDA want this parameter? I would think that if the former thought it was appropriate to delay development while investigating this issue, that the FDA would surely want to look at it from all comers. I wonder what others are thinking. FBR downgraded NKTR today, but I can't find the rationale. The results appear pretty good, absent the above measurement.

Thanks for any thoughts from anyone on this.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext